Taiyen Biotech Co., Ltd. (TPE:1737)
Taiwan · Delayed Price · Currency is TWD 31.55
+0.10 (0.32%)
May 29, 2026, 1:30 PM CST
Taiyen Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 397.04 | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 |
Depreciation & Amortization | 250.73 | 245.37 | 217.88 | 197.29 | 194.18 | 188.81 |
Other Amortization | 0.55 | 0.55 | 0.72 | 0.77 | 0.77 | 0.85 |
Loss (Gain) From Sale of Assets | 2.44 | 2.44 | 1.04 | 1.28 | 1.28 | 1.24 |
Loss (Gain) From Sale of Investments | -4.9 | -7.61 | -12.85 | -7.43 | 0.36 | 0.54 |
Provision & Write-off of Bad Debts | -22.98 | -9.66 | 84.28 | 73.56 | - | - |
Other Operating Activities | 7.66 | -2.16 | -99.33 | -82.47 | -38.21 | 24.4 |
Change in Accounts Receivable | 103.4 | -14.97 | 79.84 | -85.84 | 104.75 | -215.15 |
Change in Inventory | -94.8 | 8.72 | -80.03 | -2.9 | -25.23 | -97.12 |
Change in Accounts Payable | 1.14 | -57.26 | 25.68 | 21.35 | -104.6 | 187.74 |
Change in Unearned Revenue | -63.68 | -39.58 | 11.73 | -4.2 | 23.21 | 45.84 |
Change in Other Net Operating Assets | 63.52 | -93.67 | 59.64 | 42.74 | -2.52 | 69.71 |
Operating Cash Flow | 640.13 | 432.05 | 660.12 | 454.54 | 580.69 | 600.08 |
Operating Cash Flow Growth | 14.65% | -34.55% | 45.23% | -21.72% | -3.23% | 76.83% |
Capital Expenditures | -308.98 | -300.16 | -307.61 | -341.65 | -246.11 | -388.79 |
Sale of Property, Plant & Equipment | 0.17 | 0.17 | 0.01 | - | 0.14 | 0.27 |
Sale (Purchase) of Intangibles | -5.2 | -1.63 | - | -3.48 | -0.49 | -2.02 |
Sale (Purchase) of Real Estate | - | - | - | - | - | -1 |
Investment in Securities | -29.45 | -28.01 | 14.07 | -29.29 | 1.27 | 28.79 |
Other Investing Activities | 53.26 | 58.2 | 5.77 | 35.12 | 15.56 | 11.37 |
Investing Cash Flow | -290.19 | -271.43 | -287.76 | -339.3 | -229.64 | -351.38 |
Short-Term Debt Issued | - | 184 | 350 | 290 | 440 | 615.6 |
Long-Term Debt Issued | - | - | - | 20 | 25.26 | - |
Total Debt Issued | 218 | 184 | 350 | 310 | 465.26 | 615.6 |
Short-Term Debt Repaid | - | -196 | -352 | -210 | -707.53 | -358.07 |
Long-Term Debt Repaid | - | -76.26 | -25.65 | -19.83 | -15.68 | -19.95 |
Total Debt Repaid | -247.93 | -272.26 | -377.65 | -229.83 | -723.21 | -378.02 |
Net Debt Issued (Repaid) | -29.93 | -88.26 | -27.65 | 80.17 | -257.95 | 237.58 |
Common Dividends Paid | -260 | -260 | -240 | -300 | -300 | -270 |
Other Financing Activities | 24.87 | -14.53 | 1.12 | 20.61 | 9.97 | 3.98 |
Financing Cash Flow | -265.06 | -362.8 | -266.53 | -199.22 | -547.98 | -28.44 |
Foreign Exchange Rate Adjustments | 0.31 | 0.24 | 0.75 | -0.39 | 0.24 | -0.12 |
Net Cash Flow | 85.19 | -201.94 | 106.58 | -84.36 | -196.68 | 220.14 |
Free Cash Flow | 331.15 | 131.89 | 352.51 | 112.89 | 334.58 | 211.29 |
Free Cash Flow Growth | 35.56% | -62.59% | 212.26% | -66.26% | 58.35% | 183.28% |
Free Cash Flow Margin | 10.10% | 3.99% | 10.89% | 3.31% | 9.26% | 5.16% |
Free Cash Flow Per Share | 1.65 | 0.66 | 1.76 | 0.56 | 1.67 | 1.05 |
Cash Interest Paid | 3.86 | 3.86 | 6.3 | 3.3 | 4.68 | 5.73 |
Cash Income Tax Paid | 95.03 | 95.03 | 125.37 | 89.85 | 133.44 | 89.14 |
Levered Free Cash Flow | 209.73 | 86.69 | 338.77 | 167.07 | 211.65 | 180.73 |
Unlevered Free Cash Flow | 211.59 | 89.02 | 342.73 | 169.16 | 214.48 | 184.44 |
Change in Working Capital | 9.58 | -196.75 | 96.86 | -28.84 | -4.39 | -8.98 |